Clinical Trial Update: Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

This is a completed Phase 1 study of Navitoclax (ABT-263) in combination with either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Navitoclax (navitoclax)
• Rituximab (rituximab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED